Valuation: PTC Therapeutics, Inc.

Market Cap 5.3B 4.71B 4.39B 4B 7.55B 510B 7.62B 53.19B 20.61B 260B 19.88B 19.45B 836B P/E 2026 *
40.8x
P/E 2027 * 23.4x
Enterprise Value 3.43B 3.04B 2.84B 2.59B 4.88B 330B 4.93B 34.4B 13.33B 168B 12.86B 12.58B 541B EV / Sales 2026 *
2.72x
EV / Sales 2027 * 2.29x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
1 day-1.04%
1 week+1.26%
Current month-2.04%
1 month-11.60%
3 months-23.83%
6 months-6.36%
Current year-16.46%
1 week 62.3
Extreme 62.3
66.26
1 month 61.23
Extreme 61.23
71.4
Current year 61.23
Extreme 61.23
90.87
1 year 61.23
Extreme 61.23
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap. Importance
17/9/26
Section Six Partners
SellCompany -10,000 0.0120%
16/9/26 Other

Chairman

0 0%
10/9/26
Section Six Partners
SellCompany -10,000 0.0120%
Change 5-day change 1-year change 3-year change Capi.($)
-1.04%+1.26%+0.70%+198.78% 5.3B
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.79%-2.93%+24.53%+71.31% 370.25B
Weighted average by Cap. -0.60%-3.32%+30.47%+69.14%

Financials

2026 *2027 *
Net sales 1.26B 1.12B 1.04B 950M 1.79B 121B 1.81B 12.63B 4.9B 61.77B 4.72B 4.62B 199B 1.38B 1.22B 1.14B 1.04B 1.96B 133B 1.98B 13.83B 5.36B 67.62B 5.17B 5.06B 217B
Net income 145M 129M 120M 110M 207M 14B 209M 1.46B 566M 7.14B 546M 534M 22.95B 218M 194M 181M 165M 311M 21.03B 314M 2.19B 850M 10.72B 820M 802M 34.47B
Net Debt -1.87B -1.66B -1.55B -1.41B -2.67B -180B -2.69B -18.79B -7.28B -91.88B -7.02B -6.87B -295B -2.15B -1.91B -1.78B -1.62B -3.06B -207B -3.09B -21.54B -8.35B -105B -8.05B -7.88B -339B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.
Employees
991
Date Price Change Volume
02/10/26 USD 63.46 -1.04% 895,554
01/10/26 USD 64.13 -1.00% 1,197,752
30/09/26 USD 64.78 -0.28% 1,043,320
29/09/26 USD 64.96 -1.50% 900,435
28/09/26 USD 65.95 +5.23% 1,913,788
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
63.46USD
Average target price
101.79USD
Spread / Average Target
+60.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock